Skip to main content

Assembly Biosciences, Inc. (ASMB)

NASDAQ: ASMB · IEX Real-Time Price · USD
3.26 0.01 (0.31%)
Sep 21, 2021 3:19 PM EDT - Market open
Market Cap143.01M
Revenue (ttm)35.65M
Net Income (ttm)-93.56M
Shares Out44.97M
EPS (ttm)-2.43
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume484,602
Open3.24
Previous Close3.25
Day's Range3.23 - 3.29
52-Week Range3.09 - 17.50
Beta0.34
AnalystsBuy
Price Target9.71 (+197.9%)
Est. Earnings DateNov 4, 2021

About ASMB

Assembly Biosciences, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops oral therapeutic candidates for the treatment of hepatitis B virus (HBV) infection. Its product candidates include Vebicorvir to treat patients with chronic HBV infection; ABI-H2158, which is in Phase II clinical study for chronic HBV infection; ABI-H3733 that has completed Phase Ia clinical study for the treatment of HBV. The company has collaboration agreements with Allergan Pharmaceuticals International Limited; BeiGene, L...

IndustryBiotechnology
IPO DateDec 17, 2010
Employees139
Stock ExchangeNASDAQ
Ticker SymbolASMB
Full Company Profile

Financial Performance

In 2020, ASMB's revenue was $79.11 million, an increase of 395.55% compared to the previous year's $15.96 million. Losses were -$62.15 million, -36.34% less than in 2019.

Financial Statements

Analyst Forecast

According to 7 analysts, the average rating for ASMB stock is "Buy." The 12-month stock price forecast is 9.71, which is an increase of 197.85% from the latest price.

Price Target
$9.71
(197.85% upside)
Analyst Consensus: Buy

News

Assembly Bio Announces Decision to Discontinue Clinical Development of ABI-H2158

--Decision follows observation of elevated alanine transaminase (ALT) levels in Phase 2 study --Company will focus on advancing ongoing triple combination studies and earlier pipeline candidates

2 weeks ago - GlobeNewsWire

Assembly Bio Selects Fourth HBV Core Inhibitor Candidate for Advancement Into Clinical Development

SOUTH SAN FRANCISCO, Calif., Aug. 18, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

1 month ago - GlobeNewsWire

Assembly Biosciences (ASMB) Reports Q2 Loss, Lags Revenue Estimates

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 14.06% and -100.00%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Assembly Biosciences Reports Second Quarter 2021 Financial Results and Recent Highlights

SOUTH SAN FRANCISCO, Calif., Aug. 05, 2021 (GLOBE NEWSWIRE) --  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B...

1 month ago - GlobeNewsWire

Assembly Bio Announces Key Promotions to Leadership Team

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) --  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B...

1 month ago - GlobeNewsWire

Analysts Estimate Assembly Biosciences (ASMB) to Report a Decline in Earnings: What to Look Out for

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

Nobel Laureate Dr. Michael Houghton Appointed to Assembly Biosciences Board of Directors

Esteemed academic and industry virologist discovered hepatitis C virus (HCV); brings 40+ years of scientific and drug development experience Esteemed academic and industry virologist discovered hepatiti...

2 months ago - GlobeNewsWire

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., July 02, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

2 months ago - GlobeNewsWire

Assembly Biosciences to Present Data from HBV Core Inhibitor Programs at The International Liver Congress™ EASL 2021

SOUTH SAN FRANCISCO, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

3 months ago - GlobeNewsWire

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., June 04, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

3 months ago - GlobeNewsWire

Assembly Biosciences (ASMB) Reports Q1 Loss, Lags Revenue Estimates

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of 12.66% and -100.00%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Earnings Preview: Assembly Biosciences (ASMB) Q1 Earnings Expected to Decline

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

4 months ago - Zacks Investment Research

3 Net Current Asset Value Stocks

There are some investors who buy U.S.-listed equities that are trading below their liquidation value because they are convinced they can gain from these kinds of investments after the market has reasses...

Other symbols:LUMOUTSI
6 months ago - GuruFocus

Assembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV Infection

Assembly Biosciences Inc (NASDAQ: ASMB) and Arbutus Biopharma Corp (NASDAQ: ABUS) initiated a Phase 2 trial evaluating the former's vebicorvir (VBR), combined with the latter's AB-729 and standard-of-ca...

Other symbols:ABUS
6 months ago - Benzinga

Assembly Biosciences Foregoes Vebicorvir Registration Studies For Chronic Suppressive Therapy

Assembly Biosciences Inc (NASDAQ: ASMB) will not initiate Phase 3 studies of vebicorvir (VBR, or ABI-H0731) as a chronic suppressive therapy (CST), as the company wants to focus on hepatitis B therapies...

6 months ago - Benzinga

Assembly Biosciences (ASMB) Reports Q4 Loss, Lags Revenue Estimates

Assembly Biosciences (ASMB) delivered earnings and revenue surprises of -23.33% and -72.46%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Assembly Biosciences Updates Pipeline Strategy, Focusing on Finite and Curative Therapies for Chronic Hepatitis B Vir...

- Prioritizing next generation, more potent core inhibitors, triple combinations with complementary mechanisms of action, and expanding research programs to advance multiple candidates against novel tar...

6 months ago - GlobeNewsWire

Will Assembly Biosciences (ASMB) Report Negative Q4 Earnings? What You Should Know

Assembly Biosciences (ASMB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

Assembly Bio Announces Upcoming Investor Events

SOUTH SAN FRANCISCO, Calif., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

7 months ago - GlobeNewsWire

Assembly Biosciences to Wind-Down Microbiome Program

Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio Company will prioritize resources to focus on advancement of novel HBV therapeutic portfolio

9 months ago - GlobeNewsWire

Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

9 months ago - GlobeNewsWire

Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufa...

SOUTH SAN FRANCISCO, Calif., Nov. 17, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B ...

10 months ago - GlobeNewsWire

Assembly Biosciences and Door Pharmaceuticals Sign Collaboration and Option Agreement to Develop a Novel Class of HBV...

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB) and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusive, two-ye...

10 months ago - GlobeNewsWire

Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Me...

- Data show longer-term, differentiated safety profile of vebicorvir and the importance of HBV preg e n o mic ( pg ) RNA as a key biomarker , as well as highlight Assembly Bio's core inhibitor clinical ...

10 months ago - GlobeNewsWire

Why Assembly Biosciences Stock Crashed Today

The clinical-stage biotech had a big pipeline setback.

10 months ago - The Motley Fool